A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFκB activity

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Sorriento, Daniela ^a   Campanile, Alfonso ^a   Santulli, Gaetano ^a   Leggiero, Eleonora ^b   Pastore, Lucio ^a,b   Trimarco, Bruno ^a   Iaccarino, Guido ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSACTIVATOR RH PROTEIN; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR KINASE 5; GRK5 PROTEIN, HUMAN; LIPOCORTIN 5; RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; GENETICS; INFLAMMATION; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROTEIN TERTIARY STRUCTURE; STAINING; TUMOR CELL LINE; VASCULARIZATION;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

ADENOVIRIDAE; ANIMALS; ANNEXIN A5; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; G-PROTEIN-COUPLED RECEPTOR KINASE 5; GENE PRODUCTS, TAT; HUMANS; INFLAMMATION; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; STAINING AND LABELING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71049134493     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-97     Document Type: Article

References (49)

1. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684. 10.1038/sj.onc.1209954, 17072321.
2. Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol 2006, 6:111-130. 10.1385/CT:6:2:111, 17303919.
3. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62. 10.1038/nrm2083, 17183360.
4. Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999, 18:6842-6844. 10.1038/sj.onc.1203237, 10602459.
5. Tian B, Brasier AR. Identification of a nuclear factor kappa B-dependent gene network. Recent Prog Horm Res 2003, 58:95-130. 10.1210/rp.58.1.95, 12795416.
6. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998, 95:749-758. 10.1016/S0092-8674(00)81698-0, 9865693.
7. Baldwin AS. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001, 107:3-6. 198555, 11134170, 10.1172/JCI11891.
8. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004, 82:434-448. 10.1007/s00109-004-0555-y, 15175863.
9. Yamamoto Y, Gaynor RB. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 2001, 1:287-296. 10.2174/1566524013363816, 11899077.
10. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci USA 1993, 90:2532-2536. 46122, 8460169, 10.1073/pnas.90.6.2532.
11. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002, 73:237-243. 10.1023/A:1015872531675, 12160329.
12. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C, Bergmann MW. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005, 111:2319-2325. 10.1161/01.CIR.0000164237.58200.5A, 15870116.
13. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis: a cancer of the blood vessels?. Am J Clin Pathol 2001, 116(Suppl):S97-107.
14. Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, Bauersachs J. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 2003, 57:749-756. 10.1016/S0008-6363(02)00723-X, 12618236.
15. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310. 10.1038/nrc780, 12001991.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
17. Aggarwal B. Nuclear factor-kappaB: the enemy within. cancer cell 2004, 6:203-208. 10.1016/j.ccr.2004.09.003, 15380510.
18. Shattuck-Brandt RL, Richmond A. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res 1997, 57:3032-3039.
19. Amiri KI, Richmond A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev 2005, 24:301-313. 2668255, 15986139, 10.1007/s10555-005-1579-7.
20. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997, 15:1987-1994. 10.1038/sj.onc.1201373, 9365245.
21. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 2004, 279:54610-54619. 10.1074/jbc.M403492200, 15475567.
22. Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, Tanaka M, Katano M. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 2004, 24:675-681.
23. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8:508-513. 10.1634/theoncologist.8-6-508, 14657528.
24. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004, 10:617-624. 10.1038/nm1054, 15156202.
25. Dewan MZ, Terashima K, Taruishi M, Hasegawa H, Ito M, Tanaka Y, Mori N, Sata T, Koyanagi Y, Maeda M. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J Virol 2003, 77:5286-5294. 153944, 12692230, 10.1128/JVI.77.9.5286-5294.2003.
26. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996, 274:787-789. 10.1126/science.274.5288.787, 8864120.
27. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996, 274:784-787. 10.1126/science.274.5288.784, 8864119.
28. Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli GG, Cimini V, Galasso G, Astone D, Piscione F, Pastore L. The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proc Natl Acad Sci USA 2008, 105:17818-17823. 2584738, 19008357, 10.1073/pnas.0804446105.
29. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008, 93:4331-4341. 2582569, 18713817, 10.1210/jc.2008-1102.
30. Becker-Hapak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods 2001, 24:247-256. 10.1006/meth.2001.1186, 11403574.
31. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997, 100:2961-2969. 508507, 9399941, 10.1172/JCI119849.
32. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997, 100:2952-2960. 508506, 9399940, 10.1172/JCI119848.
33. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, Rabson AB. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002, 52:183-200. 10.1002/pros.10082, 12111695.
34. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 1995, 11:999-1003.
35. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999, 5:119-127.
36. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999, 26:119-129. 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N, 10506755.
37. Nair A, Venkatraman M, Maliekal TT, Nair B, Karunagaran D. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 2003, 22:50-58. 10.1038/sj.onc.1206043, 12527907.
38. Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991, 110:956-961.
39. Cho S, Urata Y, Iida T, Goto S, Yamaguchi M, Sumikawa K, Kondo T. Glutathione downregulates the phosphorylation of I kappa B: autoloop regulation of the NF-kappa B-mediated expression of NF-kappa B subunits by TNF-alpha in mouse vascular endothelial cells. Biochem Biophys Res Commun 1998, 253:104-108. 10.1006/bbrc.1998.9697, 9875227.
40. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 1992, 175:1181-1194. 2119220, 1314883, 10.1084/jem.175.5.1181.
41. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 1993, 90:9901-9905. 47680, 8234333, 10.1073/pnas.90.21.9901.
42. Snyder EL, Dowdy SF. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv 2005, 2:43-51. 10.1517/17425247.2.1.43, 16296734.
43. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005, 57:579-596. 10.1016/j.addr.2004.10.005, 15722165.
44. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001, 107:135-142. 199180, 11160126, 10.1172/JCI11914.
45. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, Schafer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003, 22:3243-3251. 10.1038/sj.onc.1206390, 12761494.
46. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 1991, 88:691-695. 295415, 1864978, 10.1172/JCI115354.
47. Hwang S, Ding A. Activation of NF-kappa B in murine macrophages by taxol. Cancer Biochem Biophys 1995, 14:265-272.
48. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000, 6:2573-2581.
49. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, Alitalo K. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997, 272:25176-25183. 10.1074/jbc.272.40.25176, 9312130.